Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anthem BiosciencesNSE:ANTHEM -0.93%34 Interest Coverage is 119.80 as of Mar. 2026, which is 162% above its 10-year median of 45.78. GuruFocus rates NSE:ANTHEM with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 376 Biotechnology companies, Anthem Biosciences ranks worse than 50.53% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Anthem Biosciences's
Operating Income
for the
three
months ended in Mar. 2026 was ₹2,276 Mil. Anthem Biosciences's Interest Expense for the
three
months ended in Mar. 2026 was ₹-19 Mil.
Anthem Biosciences's interest coverage for the quarter that ended in Mar. 2026 was 119.80.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Anthem Biosciences Ltd has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for Anthem Biosciences's Interest Coverage or its related term are showing as below:
NSE:ANTHEM'
s Interest Coverage Range Over the Past 10 Years
Min: 44.91 Med: 45.78 Max: 107.82
Current: 101.21
NSE:ANTHEM's Interest Coverage is ranked worse than 50.53% of 376
companies
in the Biotechnology industry
Industry Median: 104.025
vs NSE:ANTHEM: 101.21
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Anthem Biosciences Interest Coverage Related Terms
Anthem Biosciences Interest Coverage Historical Data
* Premium members only.
The historical data trend for Anthem Biosciences's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
NSE:ANTHEM vs VRTX, REGN, ALNY: Interest Coverage Comparison
For the Biotechnology subindustry, Anthem Biosciences's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anthem Biosciences Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Anthem Biosciences's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Anthem Biosciences's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anthem Biosciences (NSE:ANTHEM) has a Interest Coverage of 119.80 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Anthem Biosciences and its competitors. This is 162% above median its historical median of 45.78. Over the past decade, Anthem Biosciences' Interest Coverage has ranged from 44.91 to 107.82. According to the industry distribution chart, Anthem Biosciences ranks #190 out of 376 companies in the Biotechnology industry, placing it in the top 50.5%.
Is Anthem Biosciences' Interest Coverage too high?
Anthem Biosciences' current Interest Coverage of 119.80 is 162% above median its 10-year median of 45.78. Over the past 10 years, this metric has ranged from a low of 44.91 to a high of 107.82. The Biotechnology industry median Interest Coverage is 104.03. Anthem Biosciences' value of 119.80 is 15.2% above this industry median. Based on the distribution chart, Anthem Biosciences ranks #190 out of 376 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Anthem Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Anthem Biosciences' Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Anthem Biosciences ranks #190 out of 376 companies for Interest Coverage. This places Anthem Biosciences in the lower half of its industry. The industry median Interest Coverage is 104.03. Anthem Biosciences' value of 119.80 is 15.2% above this benchmark. Historically, Anthem Biosciences' own Interest Coverage has ranged from 44.91 to 107.82 over the past decade. While the company's 10-year median is 45.78 vs. the industry median of 104.03, Anthem Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 104.03, based on 376 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anthem Biosciences's current Interest Coverage of 119.80 is 15.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Anthem Biosciences and its competitors. For the Biotechnology industry, the median Interest Coverage is 104.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anthem Biosciences's current Interest Coverage is 119.80, which is 162% above median its own 10-year median of 45.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anthem Biosciences stock overvalued right now?
Anthem Biosciences (NSE:ANTHEM) has a current Interest Coverage of 119.80. The current Interest Coverage is 119.80, which is 162% above median its 10-year median of 45.78 and 15.2% above the Biotechnology industry median of 104.03. Anthem Biosciences' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Anthem Biosciences (NSE:ANTHEM), the current Interest Coverage is 119.80 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anthem Biosciences Ltd is an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing. It is one of the few companies in India with integrated New Chemical Entity (NCE) and New Biological Entity (NBE) capabilities across drug discovery, development, and commercial manufacturing. As a one-stop service provider, It serves a range of customers, encompassing innovator-focused emerging biotech and large pharmaceutical companies globally.
34GF Score
Get the complete analysis for NSE:ANTHEM
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ANTHEM has been successfully added to your 
